Adaptive Antimicrobial Therapy Platform
Legal Citation
Summary of the Inventive Concept
A revolutionary system for personalized antimicrobial therapy, leveraging genomic analysis, machine learning, and targeted glycopeptide delivery to combat Gram-positive bacterial infections.
Background and Problem Solved
The original patent's limitations in addressing multidrug-resistant Gram-positive bacteria, particularly S. aureus, are overcome by this new inventive concept, which tackles the emerging issue of antimicrobial resistance through adaptive therapy and precision medicine.
Detailed Description of the Inventive Concept
The adaptive antimicrobial therapy platform comprises a database of genomic information of Gram-positive bacteria, a machine learning module to predict antimicrobial resistance patterns, and a module to generate personalized treatment regimens using glycopeptides with cleavable lipophilic moieties. This system enables real-time monitoring of antimicrobial resistance, allowing for adjustments to treatment regimens in response to emerging resistance patterns. The platform also incorporates a nanoparticle-based delivery system for targeted inhalation therapy, enhancing the efficacy of glycopeptide treatment. Furthermore, the system can be integrated with bacteriophage therapy to prevent antimicrobial resistance.
Novelty and Inventive Step
The new claims introduce a paradigm shift in antimicrobial therapy by integrating genomic analysis, machine learning, and targeted glycopeptide delivery, which is a significant departure from the original patent's method of treating Gram-positive pulmonary bacterial infections. The inventive step lies in the adaptive and personalized approach to antimicrobial therapy, which addresses the growing concern of antimicrobial resistance.
Alternative Embodiments and Variations
Alternative embodiments of the platform could include the use of different machine learning algorithms, various nanoparticle designs, or integration with other antimicrobial therapies. Variations could also involve adapting the platform for different types of infections or diseases.
Potential Commercial Applications and Market
The adaptive antimicrobial therapy platform has vast commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of infectious disease treatment and prevention. The market for personalized antimicrobial therapy is expected to grow significantly, driven by the increasing need to combat antimicrobial resistance.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/14 |
| A | A61 | A61K9/008 |
| A | A61 | A61K9/0073 |
| A | A61 | A61K9/0075 |
| A | A61 | A61P31/04 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically antimicrobial drug delivery and treatment of Gram-positive bacterial infections, requiring advanced knowledge of microbiology, pharmacology, genomics, and drug design
Person of Ordinary Skill (PHOSITA) Profile
A researcher with a PhD in microbiology or pharmaceutical sciences, experienced in drug development, bacterial resistance mechanisms, and advanced drug delivery technologies, familiar with machine learning applications in precision medicine
Obviousness Rationale
A PHOSITA would recognize that the PTD's adaptive antimicrobial platform represents a predictable extension of the source patent's glycopeptide-based pulmonary infection treatment, leveraging known techniques in genomic analysis, machine learning, and targeted drug delivery to address emerging challenges in bacterial resistance management.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,597 |
|---|---|
| Title | Lipo-glycopeptide cleavable derivatives and uses thereof |
| Assignee(s) | Insmed Incorporated |